LCP
IMMU

Lamond Capital Partners’s Immunomedics Inc IMMU Stock Holding History

Lamond Capital Partners’s Portfolio IMMU Stock Details IMMU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-100,000
Closed -$307K – 5
2015
Q4 		$307K Buy
+100,000
New +$279K 0.46% 7

Other funds holding IMMU

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Lamond Capital Partners's IMMU Position: Q1 2016 in Review

Lamond Capital Partners sold out of Immunomedics Inc (IMMU) in Q1 2016, closing a stake of 100,000 shares — an estimated $307K sold.

Lamond Capital Partners first reported a position in IMMU in Q4 2015 and held it in 1 quarter. The position peaked at $307K in Q4 2015. 87 funds tracked by Wall St. Rank hold IMMU as of Q1 2016.

  • Lamond Capital Partners reported no remaining Immunomedics Inc position as of Q1 2016 after selling out during the quarter.
  • Lamond Capital Partners sold 100,000 Immunomedics Inc shares in Q1 2016, an estimated $307K.
  • Lamond Capital Partners first reported a position in Immunomedics Inc in Q4 2015 and held it in 1 quarter.
  • Lamond Capital Partners's Immunomedics Inc position peaked at $307K in Q4 2015.
  • 87 funds tracked by Wall St. Rank held Immunomedics Inc as of Q1 2016.

Based on Lamond Capital Partners's 13F filing for Q1 2016, filed 5 May 2016.